Microparticle‐Enabled Local Sustained Delivery of Paroxetine for Osteoarthritis Treatment

Osteoarthritis (OA) is a prevalent joint disease characterized by irreversible cartilage degradation, chronic pain, and reduced quality of life. Current treatments, including nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids, are largely palliative, ineffective for some patients, and associated with adverse effects. We have shown that paroxetine (Px), an FDA-approved antidepressant, has potential as a disease-modifying OA drug by inhibiting the G protein-coupled receptor kinase 2 (GRK2). Elevated GRK2 activity drives inflammation, extracellular matrix degradation and cartilage damage in OA. By inhibiting GRK2, Px suppresses cartilage degeneration, enhances chondrocyte anabolic activity, and reduces inflammation in the OA joint. In this study, we develop a local, slow-release drug delivery system that harnesses the therapeutic benefits of Px for OA treatment via microfluidic-assisted encapsulation in size-controlled poly(lactic-co-glycolic acid) (PLGA) microparticles (MP). In vitro studies show that the drug release profile is controlled by tuning the MP fabrication parameters. Efficacy testing shows that Px-eluting PLGA microparticles (MP-Px) decrease fibroblast cell migration and proliferation in vitro. In vivo, the intra-articular implantation of MP-Px in the clinically relevant destabilization of medial meniscus mouse OA model decreases chondrocyte apoptosis and has some anti-inflammatory effects in the acute phase of OA. Safranin O staining indicates mild staining loss in MP-treated groups, warranting further assessment of cartilage-matrix safety with long-term use. Importantly, serum Px levels remain low following MP-Px treatment compared with intraperitoneally administered Px (IP-Px). To the best of our knowledge, this biomaterial provides the first local intra-articular delivery of Px. These short-term findings in mice support further preclinical evaluation of MP-Px, including its effects on the cartilage matrix and long-term efficacy.

Authors

Institutions

Publication Details

Journal
Advanced Healthcare Materials
Published
2026-11-16
DOI
https://doi.org/10.1002/adhm.71976
Primary Topic
Osteoarthritis Treatment and Mechanisms
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Microparticle‐Enabled Local Sustained Delivery of Paroxetine for Osteoarthritis Treatment

Dongxiao Sun, Fadia Kamal, Roya Koshani, Arian Jaberi et al.
Advanced Healthcare Materials
Osteoarthritis Treatment and Mechanisms
article

Microparticle‐Enabled Local Sustained Delivery of Paroxetine for Osteoarthritis Treatment

Dongxiao Sun, Fadia Kamal, Roya Koshani, Arian Jaberi, Zaman Ataie, Amir Sheikhi, Tarek Haj Shehadeh, Jung Hwan Kim
article en

Abstract

Osteoarthritis (OA) is a prevalent joint disease characterized by irreversible cartilage degradation, chronic pain, and reduced quality of life. Current treatments, including nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids, are largely palliative, ineffective for some patients, and associated with adverse effects. We have shown that paroxetine (Px), an FDA-approved antidepressant, has potential as a disease-modifying OA drug by inhibiting the G protein-coupled receptor kinase 2 (GRK2). Elevated GRK2 activity drives inflammation, extracellular matrix degradation and cartilage damage in OA. By inhibiting GRK2, Px suppresses cartilage degeneration, enhances chondrocyte anabolic activity, and reduces inflammation in the OA joint. In this study, we develop a local, slow-release drug delivery system that harnesses the therapeutic benefits of Px for OA treatment via microfluidic-assisted encapsulation in size-controlled poly(lactic-co-glycolic acid) (PLGA) microparticles (MP). In vitro studies show that the drug release profile is controlled by tuning the MP fabrication parameters. Efficacy testing shows that Px-eluting PLGA microparticles (MP-Px) decrease fibroblast cell migration and proliferation in vitro. In vivo, the intra-articular implantation of MP-Px in the clinically relevant destabilization of medial meniscus mouse OA model decreases chondrocyte apoptosis and has some anti-inflammatory effects in the acute phase of OA. Safranin O staining indicates mild staining loss in MP-treated groups, warranting further assessment of cartilage-matrix safety with long-term use. Importantly, serum Px levels remain low following MP-Px treatment compared with intraperitoneally administered Px (IP-Px). To the best of our knowledge, this biomaterial provides the first local intra-articular delivery of Px. These short-term findings in mice support further preclinical evaluation of MP-Px, including its effects on the cartilage matrix and long-term efficacy.

Advanced Healthcare Materials
Pennsylvania State University (US), Penn State Milton S. Hershey Medical Center (US)
Osteoarthritis Treatment and Mechanisms
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon